Precigen, Inc. (PGEN): R&D Expense
$41.33M
Year ended 2025-12-31
$32.29M
Trailing 12 months to 2026-06-30
-11.9%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.33M | -22.1% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $53.07M | +9.2% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $48.61M | n/a | 2026-03-25, From 2023-01-01 |
| No annual figure between 2018-12-31 and 2023-12-31. | |||
| 2018-12-31 | $404.59M | +182.5% | 2019-03-01, From 2018-01-01 |
| 2017-12-31 | $143.21M | +27.7% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $112.14M | -24.0% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $147.48M | +150.0% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $58.98M | +22.5% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $48.14M | -24.8% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $64.03M | -8.8% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $70.23M | n/a | 2014-03-31, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $125.90M | +84.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $73.97M | +25.3% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $681.81M | +23.9% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
Compare PGEN, PRTA, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗